WEBULL
WebtradeDownload

Astrana Health (ASTH), What Is Behind The Fresh Attention?

Simply Wall St · 2d ago

Astrana Health (ASTH) drew fresh attention after Alignment Health Plan agreed to a new provider arrangement that will widen in-network primary and specialty care access for Medicare Advantage seniors across seven California counties.

Astrana Health’s new Alignment partnership lands after a volatile stretch, with the share price up 46.31% year to date but giving back ground over the past quarter as the 90 day share price return declined 18.83% and the 1 year total shareholder return reached 11.85%.

Scan how Astrana Health compares with other potential breakout healthcare plays by running your filters against our curated list of solid balance sheet and fundamentals (25 results) list.

Astrana Health now trades at a steep discount to both analyst targets and some intrinsic value estimates after a choppy run. Is that a mispricing of its Medicare story, or a fair warning label on the risk?

Most Popular Narrative: 29% Undervalued

At a last close of $36.90 against a widely followed fair value estimate of $51.67, Astrana Health is framed as materially discounted. That gap hinges on how durable its full risk and cash flow engine really is.

The main thing that has to go right is that Astrana Health continues to convert and manage more members in full-risk arrangements while its AI-enabled operating system keeps driving G&A efficiency, free cash flow generation, and successful integration of deals like Prospect despite ongoing Medicaid churn and cybersecurity scrutiny.

See why 6 investors see Astrana Health as 29% undervalued.

Result: Fair Value of $51.67 (UNDERVALUED)

Still, the Astrana Health story could be knocked off course if reimbursement on Medicare or Medicaid tightens or if integration and cybersecurity issues escalate costs.

Find out about the key risks to this Astrana Health narrative.

Another View: Astrana Health Through The P/E Lens

There is a very different story when Astrana Health is viewed through its P/E ratio. The stock trades at about 46.5x earnings compared with a 28.3x peer average and a 24.9x US Healthcare benchmark. The fair ratio sits nearer 35.8x. That richer multiple could signal investors are already paying up for execution, so how much of the upside case is already in the price?

To see how those earnings multiples stack up against the underlying numbers, including where valuation risk might sit if expectations cool, See what the numbers say about this price — find out in our valuation breakdown.

NasdaqCM:ASTH P/E Ratio as at Oct 2026
NasdaqCM:ASTH P/E Ratio as at Oct 2026

Next Steps

Mixed messages on Astrana Health so far. If you want to move quickly and build your own stance on the stock, weigh both the upside and the caution signals by reviewing the 4 key rewards and 1 important warning sign

Looking For More Astrana Health Style Ideas?

If you want to keep sharpening your watchlist, do not stop at Astrana Health. Let the data surface fresh angles before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.